1-(2-Amino-5-fluorophenyl)ethanone CAS#2343-25-1
Catalog No.:ALS11698
Aolisenchem provides chemical intermediates 1-(2-Amino-5-fluorophenyl)ethanone CAS#2343-25-1, it is a building block used for the synthesis of various pharmaceutical compounds.
Specifications of 1-(2-Amino-5-fluorophenyl)ethanone CAS#2343-25-1
Purity: 98%
Density: 1.202 g/cm3
Boiling Point: 264.232ºC at 760 mmHg
Water: 0.5%
Properties Of 1-(2-Amino-5-fluorophenyl)ethanone CAS#2343-25-1
|
Other Names |
2-Amino-5-fluoroacetophenone |
|
CAS Number |
2343-25-1 |
|
Molecular Formula |
C8H8FNO |
|
Molecular Weight |
|
|
MDL Number |
MFCD09835333 |
Safety Information Of 1-(2-Amino-5-fluorophenyl)ethanone CAS#2343-25-1
Signal word: Warning
Emergency treatment: if inhale, please move to fresh air; if contact with skin, remove the contaminated clothing and wash the skin thoroughly with soap and water. If you feel uncomfortable, seek medical attention immediately.
If you want to know the cas number :787618 22 8, please visit our website.
As a pharmaceutical intermediates manufacturer, we will provide more high quality related products for sale, if you have needs, please contact us.
Send product request
Other supplier products
| CAS# | Catalog No.:ALS10041 Aolisenchem can provides API of R-(+)-Lansoprazole CAS#138530 94 6. This active pharmaceutical substance can be used as a ... | |
| CAS# | Catalog No.:ALS10040 Aolisenchem provides API of Olmesartan medoxomil CAS#144689 63 4. This API in pharmacy can be used as an angiotensin II re... | |
| CAS# | Catalog No.:ALS10038 Aolisenchem provides API of Erlotinib hydrochloride CAS#183319 69 9. This kind of pharmaceutical ingredients ingredients c... | |
| Tenofovir alafenamide CAS# | Catalog No.:ALS10043 Aolisenchem provides API of Tenofovir alafenamide CAS#379270 37 8. These api ingredientscan be used as a nucleotide revers... | |
| 1-Bromobut-2-yne CAS#3355-28-0 | Catalog No.:ALS10940 Aolisenchem provides chemical intermediates 1-Bromobut-2-yne CAS#3355-28-0, which can be used in the synthesis of six to eigh... |
















